MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
51.05
+2.50 (5.15%)
NASDAQ · Last Trade: Jun 5th, 1:52 AM EDT
Detailed Quote
Previous Close
48.55
Open
49.02
Bid
51.43
Ask
51.55
Day's Range
48.54 - 52.88
52 Week Range
31.42 - 58.26
Volume
1,786,641
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
401,443
Chart
About MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
MoonLake Immunotherapeutics is a biopharmaceutical company focused on developing novel therapeutics for the treatment of autoimmune and inflammatory diseases. Leveraging its advanced proprietary platform, the company works on innovative approaches to enhance patient outcomes and address unmet medical needs in this therapeutic area. By integrating cutting-edge research and development strategies, MoonLake aims to bring new treatment options to market that can significantly improve the quality of life for individuals affected by chronic diseases. Their commitment to science and patient care drives their mission to transform the landscape of immunotherapy. Read More
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff.
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake’s nanobody-based therapy in hidradenitis suppurativa (HS) and active psoriatic arthritis (PsA), two underdiagnosed diseases that have significant unmet patient needs.
Results with MoonLake Immunotherapeutics' Nanobody sonelokimab in Psoriatic Arthritis. Achieve over 60% ACR50, 40% ACR70, and 80% PASI90 by week 24. Unprecedented improvements compared to competitors.
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
